Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2015

01-02-2015 | Original Article

A randomized controlled clinical trial of formalin for treatment of chronic hemorrhagic radiation proctopathy in cervical carcinoma patients

Authors: Guang-Hong Guo, Feng-Ye Yu, Xing-Jie Wang, Fei Lu

Published in: Supportive Care in Cancer | Issue 2/2015

Login to get access

Abstract

Purpose

Chronic hemorrhagic radiation proctopathy is not uncommon after radiotherapy for cervical carcinoma. The outcomes of several treatments have been variable. Many studies demonstrate that topical treatment with 4 % formalin is effective and safe. However, a nonrandomized control study showed a high response rate and good tolerance in chronic radiation proctopathy patients treated with 10 % formalin. The optimal concentration of formalin therefore remains unclear.

Methods

To compare the effectiveness and safety of 4 and 10 % formalin for the treatment of chronic hemorrhagic radiation proctopathy, a prospective trial was conducted at the Department of Gynecology of the Affiliated Hospital of Binzhou Medical College from January 2009 to December 2012. One hundred and twenty patients with chronic hemorrhagic radiation proctopathy following radiotherapy for cervical carcinoma were recruited and randomized to receive 4 or 10 % formalin. A standard protocol was followed for formalin application. Symptom and rectoscopy scores were evaluated before and at 12 weeks after treatment.

Results

In the 4 % formalin group, 49 (86.0 %) and 53 (91.4 %) patients showed an improvement in symptom score and rectoscopy score, respectively (P = 0.36). Symptom and rectoscopy scores decreased significantly after treatment in both the 4 % formalin group and the 10 % formalin group (P < 0.001). Symptom score was correlated with rectoscopy score (P < 0.001). More patients in the 10 % group suffered treatment-related complications than did those in the 4 % group (P = 0.03).

Conclusions

For the treatment of chronic hemorrhagic radiation proctopathy, 4 % should be the preferred formalin concentration.
Literature
1.
Johnston MJ, Robertson GM, Frizelle FA (2003) Management of late complications of pelvic radiation in the rectum and anus: a review. Dis Colon Rectum 46(2):247–259PubMedCrossRef
2.
Nelamangala RVP, Javali TD, Dharanipragada K, Reddy KS, Krishnamachari S (2012) Formalin dab, the effective way of treating haemorrhagic radiation proctitis: a randomized trial from a tertiary care hospital in South India. Color Dis 14(7):876–882CrossRef
3.
Oscarsson N, Arnell P, Lodding P, Ricksten SE, Seeman-Lodding H (2013) Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. Int J Radiat Oncol, Biol, Phys 87(4):670–675CrossRef
4.
Yeoh E, Tam W, Schoeman M et al (2013) Argon plasma coagulation therapy versus topical formalin for intractable rectal bleeding and anorectal dysfunction after radiation therapy for prostate carcinoma. Int J Radiat Oncol, Biol, Phys 87(5):954–959CrossRef
5.
Denton AS, Andreyev HJ, Forbes A, Maher EJ (2002) Systematic review for non-surgical interventions for the management of late radiation proctitis. Br J Cancer 87(2):134–143PubMedCentralPubMedCrossRef
6.
Sahakitrungruang C, Patiwongpaisarn A, Kanjanasilp P, Malakorn S, Atittharnsakul P (2012) A randomized controlled trial comparing colonic irrigation and oral antibiotics administration versus 4 % formalin application for treatment of hemorrhagic radiation proctitis. Dis Colon Rectum 55(10):1053–1058PubMedCrossRef
7.
Pironi D, Panarese A, Vendettuoli M et al (2013) Chronic radiation-induced proctitis: the 4 % formalin application as non-surgical treatment. Int J Colorectal Dis 28(2):261–266PubMedCrossRef
8.
Haas EM, Bailey HR, Farragher I (2007) Application of 10 percent formalin for the treatment of radiation-induced hemorrhagic proctitis. Dis Colon Rectum 50(2):213–217PubMedCrossRef
9.
Ehrenpreis ED, Jani A, Levitsky J, Ahn J, Hong J (2005) A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum 48(1):1–8PubMedCrossRef
10.
Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R (2000) Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. Radiother Oncol 54(1):11–19PubMedCrossRef
11.
Huang EY, Lin H, Hsu HC et al (2000) High external parametrial dose can increase the probability of radiation proctitis in patients with uterine cervix cancer. Gynecol Oncol 79(3):406–410PubMedCrossRef
12.
Kintzinger C, Demoor-Goldschmidt C, Abderrahmani R, Paris F, Supiot S (2012) Radiation-induced proctitis: symptoms, pathophysiology and treatment. Cancer Radiother: J Soc Fr Radiother Oncol 16(5-6):372–376CrossRef
13.
Cullen SN, Frenz M, Mee A (2006) Treatment of haemorrhagic radiation-induced proctopathy using small volume topical formalin instillation. Aliment Pharmacol Ther 23(11):1575–1579PubMedCrossRef
14.
Liu Y, Kudo K, Abe Y et al (2008) Hypoxia expression in radiation-induced late rectal injury. J Radiat Res 49(3):261–268PubMedCrossRef
15.
Haboubi NY, Schofield PF, Rowland PL (1988) The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 83(10):1140–1144PubMed
16.
Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I (2002) The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 94(3):862–871PubMedCrossRef
17.
McElvanna K, Wilson A, Irwin T (2014) Sucralfate paste enema: a new method of topical treatment for haemorrhagic radiation proctitis. Color Dis 16(4):281–284CrossRef
18.
Zouhair A, Wiesel PH (2005) Non-surgical treatment of acute and late radiation proctitis. Rev Med Suisse 1(3):228–230PubMed
19.
Hou JK, Abudayyeh S, Shaib Y (2011) Treatment of chronic radiation proctitis with cryoablation. Gastrointest Endosc 73(2):383–389PubMedCrossRef
20.
Moawad FJ, Horwhat JD (2014) Cryotherapy for treatment of radiation proctitis. Gastrointest Endosc 79(2):209–210PubMedCrossRef
21.
Shrom SH, Donaldson MH, Duckett JW, Wein AJ (1976) Formalin treatment for intractable hemorrhagic cystitis: a review of the literature with 16 additional cases. Cancer 38(4):1785–1789PubMedCrossRef
22.
Rubinstein E, Ibsen T, Rasmussen RB, Reimer E, Sorensen BL (1986) Formalin treatment of radiation-induced hemorrhagic proctitis. Am J Gastroenterol 81(1):44–45PubMed
23.
de Parades V, Etienney I, Bauer P et al (2005) Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis—an effective but not risk-free procedure: a prospective study of 33 patients. Dis Colon Rectum 48(8):1535–1541PubMedCrossRef
24.
Luna-Perez P, Rodriguez-Ramirez SE (2002) Formalin instillation for refractory radiation-induced hemorrhagic proctitis. J Surg Oncol 80(1):41–44PubMedCrossRef
25.
Sharma B, Kumar R, Singh KK, Chauhan V (2010) Intrarectal application of formalin for chronic radiation proctitis: a simple, cheap and effective treatment. Trop Gastroenterol 31(1):37–40PubMed
26.
Metadata
Title
A randomized controlled clinical trial of formalin for treatment of chronic hemorrhagic radiation proctopathy in cervical carcinoma patients
Authors
Guang-Hong Guo
Feng-Ye Yu
Xing-Jie Wang
Fei Lu
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2401-2

Other articles of this Issue 2/2015

Supportive Care in Cancer 2/2015 Go to the issue

Review Article

The prophylactic use of Chinese herbal medicine for chemotherapy-induced leucopenia in oncology patients: a systematic review and meta-analysis of randomized clinical trials

Original Article

Length of home hospice care, family-perceived timing of referrals, perceived quality of care, and quality of death and dying in terminally ill cancer patients who died at home

Original Article

Clinical features and risk factors for development of Bacillus bacteremia among adult patients with cancer: a case-control study

Original Article

Peripherally inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study

Special Article

Development of protocol for the management of cervical cancer symptoms in resource-constrained developing countries

Original Article

Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits